C-Met Targeted Therapy of Cholangiocarcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 May 22

PMID 18494048

Citations 20

Authors

Matei-P Socoteanu

Frank Mott

Gianfranco Alpini

Arthur-E Frankel

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma continues to be a challenging disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase II trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

Citing Articles

Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma.

Wu W, Chen R, Cheng C, Wei J, Lin C, You R Pharmaceutics. 2022; 14(12).

PMID: 36559193 PMC: 9784408. DOI: 10.3390/pharmaceutics14122698.

3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors.

Claus A, Sweeney A, Sankepalle D, Li B, Wong D, Xavierselvan M Front Oncol. 2022; 12:915319.

PMID: 35875138 PMC: 9300843. DOI: 10.3389/fonc.2022.915319.

Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy.

Koustas E, Trifylli E, Sarantis P, Papavassiliou A, Karamouzis M World J Gastrointest Oncol. 2021; 13(10):1229-1243.

PMID: 34721764 PMC: 8529918. DOI: 10.4251/wjgo.v13.i10.1229.

Anticancer Activity of Fucoidan via Apoptosis and Cell Cycle Arrest on Cholangiocarcinoma Cell.

Chantree P, Na-Bangchang K, Martviset P Asian Pac J Cancer Prev. 2021; 22(1):209-217.

PMID: 33507701 PMC: 8184191. DOI: 10.31557/APJCP.2021.22.1.209.

Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.

Perez-Montoyo H Cells. 2020; 9(3).

PMID: 32143356 PMC: 7140412. DOI: 10.3390/cells9030614.

References

Olnes M, Erlich R . A review and update on cholangiocarcinoma. Oncology. 2004; 66(3):167-79. DOI: 10.1159/000077991. View

Wong L, Suh D, Frankel A . Toxin conjugate therapy of cancer. Semin Oncol. 2005; 32(6):591-5. DOI: 10.1053/j.seminoncol.2005.08.002. View

Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G . Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24(19):3069-74. DOI: 10.1200/JCO.2005.05.3579. View

Gao C, Vande Woude G . HGF/SF-Met signaling in tumor progression. Cell Res. 2005; 15(1):49-51. DOI: 10.1038/sj.cr.7290264. View

Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R . Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 2006; 136(1):78-84. DOI: 10.1016/j.jss.2006.05.031. View

Sattler M, Pride Y, Ma P, Gramlich J, Chu S, Quinnan L . A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63(17):5462-9. View

Rashid A . Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am. 2003; 11(4):995-1009. DOI: 10.1016/s1055-3207(02)00042-x. View

Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B . Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res. 2007; 24(10):1910-8. DOI: 10.1007/s11095-007-9316-2. View

Werneburg N, Yoon J, Higuchi H, Gores G . Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2003; 285(1):G31-6. DOI: 10.1152/ajpgi.00536.2002. View

10.

Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y . Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol Rep. 1999; 6(5):1051-6. DOI: 10.3892/or.6.5.1051. View

11.

Terada T, Nakanuma Y, Sirica A . Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998; 29(2):175-80. DOI: 10.1016/s0046-8177(98)90229-5. View

12.

Martens T, Schmidt N, Eckerich C, Fillbrandt R, Merchant M, Schwall R . A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006; 12(20 Pt 1):6144-52. DOI: 10.1158/1078-0432.CCR-05-1418. View

13.

Peruzzi B, Bottaro D . Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006; 12(12):3657-60. DOI: 10.1158/1078-0432.CCR-06-0818. View

14.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

15.

Sirica A . Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005; 41(1):5-15. DOI: 10.1002/hep.20537. View

16.

Cao B, Su Y, Oskarsson M, Zhao P, Kort E, Fisher R . Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 2001; 98(13):7443-8. PMC: 34688. DOI: 10.1073/pnas.131200498. View

17.

Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T . Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006; 66(3):1721-9. DOI: 10.1158/0008-5472.CAN-05-3329. View

18.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

19.

Smolen G, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H . Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006; 103(7):2316-21. PMC: 1413705. DOI: 10.1073/pnas.0508776103. View

20.

Farazi P, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho R . Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006; 66(13):6622-7. DOI: 10.1158/0008-5472.CAN-05-4609. View